Clinical trial NCT00519012 - References

Depression — Benefits of Switching Antidepressants Following Early Nonresponse

Citation(s)

•   Cusin C, Fava M, Amsterdam JD, Quitkin FM, Reimherr FW, Beasley CM Jr, Rosenbaum JF, Perlis RH
  Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications. J Clin Psychiatry. 2007 Jan;68(1):52-7.
•   Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, Frazer A
  Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology. 2004 Mar;29(3):566-79.
•   Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M
  Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry. 1995 Oct;152(10):1500-3.
•   Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M
  A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol. 2006 Feb;26(1):56-60.
•   Szegedi A, Müller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O
  Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry. 2003 Apr;64(4):413-20.
•   Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z
  Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry. 2006 Nov;63(11):1217-23. Review.

Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2

Details for clinical trial NCT00519012